University of Alberta
Welcome,         Profile    Billing    Logout  
 497 Trials 
1650 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erba, Harry P
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
NCT05554393: Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Recruiting
2
153
Canada, US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia
12/25
12/25
NCT06317649: Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Recruiting
2
147
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Gilteritinib, ASP 2215, ASP-2215, ASP2215, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia
10/25
10/25
MyeloMATCH, NCT05554406: Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A Treatment Trial)

Recruiting
2
335
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Echocardiography, EC, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
03/27
03/27
S1905, NCT04315324: Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Recruiting
2
39
US
AKR1C3-activated Prodrug OBI-3424, AKR1C3-activated Prodrug TH-3424, Aldo-keto Reductase 1c3-activated Prodrug OBI-3424, OBI 3424, OBI-3424, OBI3424, TH 3424, TH-3424, TH3424
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
08/28
08/32
MyeloMATCH, NCT05564390: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH ( Screening Trial)

Recruiting
2
2000
Canada, US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Best Practice, standard of care, standard therapy, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Echocardiography, EC, Enasidenib, AG 221, AG-221, AG221, CC-90007 Free Base, Gilteritinib, ASP 2215, ASP-2215, ASP2215, Liposome-encapsulated Daunorubicin-Cytarabine, CPX 351, CPX-351, CPX351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
05/29
05/29
NCT04358393: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Recruiting
1/2
69
US
APG-115, 5-azacitidine, Vidaza, Azadine
Ascentage Pharma Group Inc.
AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
12/24
12/25
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Europe, Canada, Japan, US, RoW
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
FRIDA, NCT05546580: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Checkmark First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Nov 2022 - Nov 2022: First-patient-in of FRIDA trial in combination with gilteritinib for r/r AML
Recruiting
1
50
US
Iadademstat, ORY-1001, RO7051790, Gilteritinib Oral Tablet, XOSPATA®
Oryzon Genomics S.A.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/25
11/25
Chang, Helena R
SOUND, NCT05701098: Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)

Recruiting
N/A
116
Canada, US
Break Wave extracorporeal lithotripsy
SonoMotion
Kidney Stone, Urolithiasis, Nephrolithiasis, Renal Calculi, Kidney Calculi, Nephrolith, Urinary Calculi
12/24
01/25
Shapiro, James
NCT03182426: Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Completed
1/2
22
Canada
Plerixafor, Mozobil, Alemtuzumab, Lemtrada, Anakinra, Kineret, Etanercept, Enbrel, Liraglutide, Victoza
University of Alberta, Alberta Innovates Health Solutions
Diabetes Mellitus, Type 1
07/24
07/24
NCT03089840: Normothermic Liver Preservation Trial

Completed
1/2
106
Canada
OrganOx metra
University of Alberta
End Stage Liver Disease, Liver Diseases
07/24
07/24
NCT03444064: PolyTreg Immunotherapy in Islet Transplantation

Completed
1
11
Canada
PolyTregs, Ex vivo Expanded Autologous CD4+CD127lo/-CD25+ Polyclonal Regulatory T cells
University of Alberta, Diabetes Research Institute Foundation, Liana's Dream Foundation, Juvenile Diabetes Research Foundation, Alberta Diabetes Institute
Diabetes, Diabetes Mellitus, Type 1
08/24
12/24
NCT05073302: Device-Less Technique in Islet Transplantation

Recruiting
1
5
Canada
Implantation of Nylon catheter (Device-less sentinel unit)
University of Alberta, Juvenile Diabetes Research Foundation
Type 1 Diabetes
01/25
01/25
cePolyTregs, NCT05349591: CePolyTregs in Islet Transplantation

Active, not recruiting
1
11
Canada
cePolytreg
University of Alberta, Juvenile Diabetes Research Foundation, Juvenile Diabetes Research Foundation Canadian Clinical Trial Network
Diabetes Type1
05/26
05/26
NCT03073577: Islet Transplantation Using PKX-001

Recruiting
1
6
Canada
Antiaging Glycopeptide, PKX-001, AAGP
University of Alberta, ProtoKinetix Inc.
Type 1 Diabetes Mellitus
03/25
03/25
Ho, Chester H
NCT05255679: Early FES Cycling in Acute Spinal Cord Injury for Neuromuscular Preservation and Neurorecovery

Completed
N/A
35
Canada
Early FES, Delayed FES
University of Alberta, Royal Alexandra Hospital, Glenrose Foundation
Acute Spinal Cord Injury
08/23
10/23
Hart, Robert
HREBA.CC-23-0001, NCT06133374: Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples

Recruiting
N/A
130
Canada
University of Calgary, Qualisure Diagnostics Inc., Alberta Health services
Papillary Thyroid Cancer
05/28
05/28
Brandwein, Joseph
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
TWT-202, NCT04730258: A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Recruiting
1/2
72
Canada, US, RoW
CFI-400945, CFI-400945 fumarate, 945, 400945, Azacitidine
Treadwell Therapeutics, Inc
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
01/26
01/26
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation

Recruiting
1/2
70
Europe, Canada, Japan, US, RoW
DSP-5336
Sumitomo Pharma America, Inc.
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
01/25
02/25
Mehta, Vivek
MUST, NCT04327817: Multifidus PET Scan Study

Recruiting
4
20
Europe
Multifidus stimulator, ReActiv8 stimulator
Barts & The London NHS Trust, Mainstay Medical
Low Back Pain
10/25
10/25
CHRONOS, NCT04943770: Evaluating the Effect of Spinal Cord Stimulation Frequency on Fast-Acting Sub-perception Therapy (FAST) for Chronic Pain

Withdrawn
N/A
20
Europe
Spinal cord stimulator implant, Boston Scientific Wavewriter, Healing period, WaveWriter™ Alpha Spinal Cord Stimulator (SCS) system
Barts & The London NHS Trust, Boston Scientific Corporation
Neuropathic Low Back Pain
07/23
07/23
NCT06022848: Quantitative Sensory Testing and Occipital Nerve Stimulator

Recruiting
N/A
40
Europe
occipital nerve stimulator, Quantitative sensory testing
Dr Theresa Wodehouse
Migraines
11/23
11/24
NCT02844465: Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

Completed
N/A
167
US
Visualase MRI-Guided Laser Ablation, Visualase System, Visualase procedure, Laser interstitial thermal therapy, Stereotactic laser ablation
MedtronicNeuro
Temporal Lobe Epilepsy
12/23
12/23
NCT03818074: High Frequency (1000Hz) Spinal Cord Stimulation in Neuropathic Pain Patients With Virgin Back

Completed
N/A
30
Europe
Boston Wavewriter 1000Hz Spinal cord Stimulation
Barts & The London NHS Trust, Boston Scientific Corporation
Neuropathic Pain, Low Back Pain
07/24
07/24
Courneya, Kerry S
BRAVE, NCT04593862: Bladder Cancer and ExeRcise Training During IntraVesical ThErapy

Completed
2
25
Canada
High-Intensity Interval Training
University of Alberta, Northern Alberta Urology Centre, Cross Cancer Institute
Bladder Cancer
08/24
08/24
LIFTING2, NCT06289049: Heavy Strength Training in Head and Neck Cancer Survivors

Not yet recruiting
2
60
Canada
Experimental, Exercise Group
University of Alberta
Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma
01/26
04/26
INTERVAL, NCT02730338: INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer ( - GAP4)

Active, not recruiting
N/A
866
Europe, Canada, US, RoW
High intensity aerobic and resistance training, Psychosocial support
Movember Foundation, University of California, San Francisco, Edith Cowan University, King's College London, Centre hospitalier de l'Université de Montréal (CHUM)
Metastatic Prostate Cancer
10/25
10/26
NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Active, not recruiting
N/A
889
Europe, Canada, US, RoW
exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing
Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast
Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise
12/29
12/30
Wong, Eric
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
ImmuneSense, NCT04485949: A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Active, not recruiting
2
93
US
IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide
Imvax
Glioblastoma
01/25
07/27
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
02/25
03/25
NCT04129515: NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Not yet recruiting
1/2
30
US
NovoTTF-200A, Pembrolizumab, Keytruda®
Brown University, NovoCure Ltd.
Metastatic Melanoma, Melanoma Brain Metastasis
03/26
01/27
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
VICTORY, NCT05005299: Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

Recruiting
1
18
RoW
Venetoclax, Venclaxta, Fludarabine, Cyclophosphamide
Melbourne Health
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma
03/26
03/26
Morrish, Donald W
NCT01876771: A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Recruiting
2
500
Canada
[177]Lu-DOTA-TATE, Lu-DOTA-TATE
AHS Cancer Control Alberta
Carcinoma, Neuroendocrine
12/33
12/33
NCT03145857: A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Recruiting
1/2
500
Canada
[68]Ga-HA-DOTATATE, Gallium-68 high affinity-DOTATATE, Gallium-68 DOTA-3-iodo-Tyr(3)-octreotate
AHS Cancer Control Alberta
Neuroendocrine Tumors
12/31
12/31
NCT01763554: Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

Active, not recruiting
N/A
115
Canada
Lu-177 DOTA-TATE
AHS Cancer Control Alberta, Cross Cancer Institute
Neuroendocrine Tumors, NET
12/25
12/25
Douketis, James
COBRRA, NCT03266783: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Recruiting
4
2760
Europe, Canada, RoW
Apixaban, Eliquis, Rivaroxaban, Xarelto
Ottawa Hospital Research Institute, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Institutes of Health Research (CIHR)
Venous Thromboembolism
12/24
12/24
Sharma, Arya M
PREMIUM, NCT03235804: The Impact of a Powdered Meal Replacement on Metabolism and Gut Microbiota

Completed
N/A
88
Canada
Soy protein, honey and yogurt.
University of Alberta, Almased Wellness GmbH
Dietary Modification
12/23
12/23
Paterson, David
MERINO II, NCT02437045: Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response

Completed
4
100
RoW
Meropenem, Merrem, Meronem, Piperacillin-tazobactam combination product, Zosyn, Tazocin
The University of Queensland
Bloodstream Infections
12/20
12/20
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
RAPID, NCT05979545: EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics

Recruiting
4
1900
RoW
Rapid Diagnostics, BioFire FilmArray BCID2, BioFire FilmArray Pneumonia Plus Panel, BioFire FilmArray Pneumonia Panel
National University of Singapore, Pfizer, Biomerieux inc
Blood Stream Infections, Ventilator Associated Pneumonia, Healthcare Associated Infection, Carbapenem-Resistant Enterobacteriaceae Infection, Hospital-acquired Pneumonia
10/26
12/26
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
GAMECHANGER, NCT03869437: RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

Completed
2
513
RoW
Cefiderocol, S-649266, Best Available Therapy
The University of Queensland, Shionogi
Bloodstream Infections
11/23
01/24
NCT05256316: Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

Completed
N/A
790
US, RoW
Previously admitted COVID-19 patients in intensive care units
The University of Queensland, Merck Sharp & Dhome (Australia) Pty. Ltd., Christian Medical College, Vellore, India, Tan Tock Seng Hospital, Royal Brisbane and Women's Hospital, Siriraj Hospital, University of North Carolina, Chapel Hill
COVID-19
12/22
12/22
Shafran, Stephen
CINNAMON, NCT06039579: Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Completed
2
44
Europe, Canada, US, RoW
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo
ViiV Healthcare
HIV Infections
06/24
06/24
Hill, Michael D
PLATINUM, NCT04443608: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Terminated
4
115
US
Patiromer Powder for Oral Suspension [Veltassa], Active drug, Placebo, Inactive substance
Comprehensive Research Associates
Hyperkalemia
03/23
06/23
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
ACT-WHEN, NCT06320431: ACT-GLOBAL THROMBOLYSIS (-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

Recruiting
3
4000
Canada, RoW
Tenecteplase, TNKase, Metalyse
University of Calgary, The George Institute for Global Health, Australia
Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
09/30
12/30
ACT-GLOBAL, NCT06352632: Adaptive Platform Trial for Stroke

Recruiting
3
20000
Canada, RoW
Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase, Conservative Blood Pressure Control, Moderate Blood Pressure Control, Intensive Blood Pressure Control, Placebo, NoNO-42, No deferoxamine mesylate and no colchicine, Deferoxamine mesylate only, Colchicine only, Both deferoxamine mesylate and colchicine
The George Institute, University of Calgary, Berry Consultants
Stroke
09/34
09/34
TEMPO-2, NCT02398656: A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

Completed
3
1274
Europe, Canada, RoW
Tenecteplase, TNK-tPA, Antiplatelet treatment, ASA, Clopidogrel
University of Calgary
Stroke, Acute
01/24
04/24
ENDOLOW, NCT04167527: Endovascular Therapy for Low NIHSS Ischemic Strokes

Recruiting
2/3
200
Europe, Canada, US
Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device, EmboTrap III, Initial medical management (iMM)
Emory University, University of Calgary, University of Cincinnati, Heidelberg University, Children's Hospital Medical Center, Cincinnati
Cerebral Ischemia
12/24
12/24
NCT05123755: Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Recruiting
2a
120
US
AV-001 Injection, AV-001 Placebo Injection
Vasomune Therapeutics, Inc.
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
12/24
03/25
KOURAGE, NCT06374797: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"

Recruiting
2
150
US
Auxora, Placebo
CalciMedica, Inc.
Acute Kidney Injury
08/25
08/25
RAISE, NCT06226805: Study of BB-031 in Acute Ischemic Stroke Patients

Recruiting
2
156
US, RoW
BB-031, DTRI-031, Placebo, Saline
Basking Biosciences, Inc.
Acute Ischemic Stroke
12/26
03/27
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT06403267: NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis with or Without Endovascular Thrombectomy

Recruiting
2
600
Canada
NoNO-42, Placebo, Control
NoNO Inc.
Acute Ischemic Stroke
05/26
05/26
ACST-2, NCT00883402: Carotid Endarterectomy Versus Carotid Artery Stenting in Asymptomatic Patients

Active, not recruiting
N/A
3638
Europe, Canada, Japan, US, RoW
CEA, CAS
University of Oxford, NHS Health Technology Assessment Programme, BUPA Foundation, British Heart Foundation
Carotid Stenosis
12/20
12/25
Tension, NCT03094715: Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window

Terminated
N/A
253
Europe, Canada, RoW
Thrombectomy, Mechanical thrombectomy, Best medical care, Control group
University Hospital Heidelberg, Karolinska University Hospital, Eppdata GmbH Hamburg, Germany, Aarhus University Hospital, Medical University Innsbruck, Groupe Hospitalier Pitie-Salpetriere, Oslo University Hospital, University Hospital, Martin, Charles University, Czech Republic, Hospices Civils de Lyon, CHU de Reims, Epidemiological and Clinical Research Information Network, STROKE ALLIANCE FOR EUROPE, International Consortium for Health Outcome Measurement, Inc., Europan Society for Minimally Invasive Neurological Therapy, Universitätsklinikum Hamburg-Eppendorf
Stroke, Acute, Cerebral Stroke, Cerebrovascular Stroke, Apoplexy; Brain
05/23
11/23
ENCHANTED3/MT, NCT06352619: Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial

Recruiting
N/A
2000
Canada, RoW
Conservative SBP Control, Moderate SBP Control, Intensive SBP Control
The George Institute, University of Calgary, Changhai Hospital
Ischemic Stroke, Acute
05/26
05/26
Andersen, Henning R
SIDEC, NCT04589299: Subcutaneous Immunoglobulin in De-novo CIDP

Recruiting
4
60
Europe
Immunoglobulin
University of Aarhus, Rigshospitalet, Denmark, Aarhus University Hospital, Odense University Hospital, Aalborg University Hospital
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
12/30
12/30
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
REACH, NCT05397470 / 2022-000389-16: Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Terminated
3
260
Europe, Canada, US
Losmapimod, Placebo oral tablet
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
11/24
11/24
SYNAPSE-CMT, NCT06482437: Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Recruiting
2
80
Europe, US
NMD670, Placebo
NMD Pharma A/S
Charcot-Marie-Tooth Disease
03/26
03/26
NCT05685927: Muscular Deficits of Diabetic Myopathy

Recruiting
N/A
108
Europe
6-months of medically assisted glycemic improvement, Bariatric surgery
University of Aarhus
Diabetes Mellitus, Obesity, Chronic Hyperglycaemia, Weight Loss, Diabetic Myopathy, Sarcopenia
09/25
12/25
Jacobson, Ira M
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
ARGON-2, NCT04378010 / 2019-003876-38: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Terminated
2b
98
Europe, Canada, US, RoW
EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo
Enanta Pharmaceuticals, Inc, Enanta Pharmaceuticals, Inc.
Non-Alcoholic Steatohepatitis
10/21
11/21
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05856890: HepB MAb19 in Individuals with Chronic Hepatitis B Infection

Recruiting
1
37
US
HepB mAb19, Sterile Saline
Rockefeller University, NYU Langone Health
Hepatitis B Virus, Hepatitis B
12/27
03/28
Maksymowych, Walter
UP-SPOUT, NCT06454188: A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

Not yet recruiting
4
100
NA
Upadacitinib 15 MG [Rinvoq], Rinvoq, Placebo
CARE ARTHRITIS LTD.
Psoriatic Arthritis, Spondyloarthritis, Axial
12/26
12/26
IMPACT, NCT04347798: IMPact of Antimalarials on Covid-19 Infections in RAPPORT

Completed
N/A
773
Canada
Hydroxychloroquine/Chloroquine
University of Alberta
Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis, Hydroxychloroquine
06/22
06/22
Tsuyuki, Ross T
NCT04979546: Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis

Completed
N/A
237
Canada
Intensive Use of Patient Reported Outcome Measures and Open PROM Availability to Treating Neurologist, Conservative Use of Patient Reported Outcome Measures and Blinded PROM Availability to Treating Neurologist
University of Alberta, University Hospital Foundation
Multiple Sclerosis, Anxiety, Depression, Patient Satisfaction
04/24
04/24
NCT05991414: The Effect of Pharmacist-Initiated Home Blood Pressure Monitoring on Blood Pressure Control in Women

Recruiting
N/A
368
Canada
Home blood pressure monitor, Enhanced community pharmacist care, Usual pharmacist care
University of Alberta
Hypertension
01/25
12/25
PRxOACT, NCT06405880: Pharmacist Case Finding and Intervention for Vascular Prevention Trial

Recruiting
N/A
982
Canada
Pharmacist-led care pathway
University of Alberta
Cardiovascular Risk Factors, Blood Pressure, Cardiovascular Disease, Diabetes, Dyslipidemia
12/26
06/27
PACE-OA, NCT06681142: Pharmacist-physiotherapist Collaborative Management for Early Knee Osteoarthritis

Not yet recruiting
N/A
125
NA
Pharmacy-Physiotherapy Intervention
University of Alberta
Osteoarthritis (OA) of the Knee, Physiotherapy, Pharmacy
09/26
09/27
PAUSE, NCT06433414: Sick Day Medication Management Mobile App Study

Not yet recruiting
N/A
320
NA
PAUSE App
University of Alberta, University of Calgary
Chronic Condition, Adverse Event
11/25
11/25
Braam, Branko
DIURESED, NCT05915286: Diuretic Use in Hemodialysis Patients With Residual Renal Function

Suspended
4
34
Canada
Furosemide, Chlorthalidone
University of Alberta
End Stage Renal Disease on Dialysis
02/25
02/25
NCT05378750: Fluid Overload Management and Vascular Stiffness in Chronic Kidney Disease Patients With Hypertension

Terminated
N/A
2
Canada
Diuretic algorithm
University of Alberta
Hypertension
11/23
11/23
Tremblay, Alain
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
NCT02431962: Alberta Lung Cancer Screening Program

Active, not recruiting
N/A
800
Canada
Computed Tomography, Active smokers - Smoking cessation arm, Active smokers - Control arm
University of Calgary, Alberta Cancer Foundation
Lung Neoplasms, Respiratory Tract Neoplasms
12/19
12/22
NCT03809169: Peripheral EBUS With ROSE vs no ROSE; Slim Bronchoscope Without Guide Sheath vs Standard Bronchoscope With Guide Sheath

Completed
N/A
186
Canada
Rapid on-site evaluation (ROSE), Slim bronchoscope without a guide sheath, Ultrathin bronchoscope with pEBUS, Standard pEBUS with guide sheath
University of Calgary, McGill University, Laval University
Peripheral Pulmonary Lesions, Lung Cancer
03/24
09/24
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/24
12/26
Mayers, Irvin
TERAA, NCT06705764: Tezepelumab in the Treatment of Emergency Room Asthma in Adults

Not yet recruiting
4
100
Canada
Tezepelumab, Placebo
University of Alberta, AstraZeneca
Severe Asthma
11/25
11/26
Haqq, Andrea M
NCT04578652: Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance

Recruiting
3
90
Canada
Metformin 850 mg oral tablet bid, Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.
University of Alberta
Obesity, Childhood, Insulin Resistance
09/25
09/25
NCT06075667: A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Recruiting
3
150
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
10/26
NCT04150991: Fiber Intervention on Gut Microbiota in Children With Prader-Willi Syndrome

Completed
N/A
14
Canada
Fiber intervention, Placebo treatment
University of Alberta
Prader-Willi Syndrome, Hyperphagia
02/23
02/23
MiTy Tykes, NCT05025852: The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

Recruiting
N/A
220
Canada, RoW
Mount Sinai Hospital, Canada, Sunnybrook Research Institute, Canadian Institutes of Health Research (CIHR)
Diabetes Mellitus, Type 2, Pregnancy in Diabetic, Child Obesity, Child Development
05/26
05/26
Eves, Neil D
H18-01575, NCT05553223: Micro-doses of Physical Activity for COPD

Recruiting
N/A
20
Canada
Microdoses of activity
University of British Columbia
Chronic Obstructive Pulmonary Disease, Endothelial Dysfunction, Vascular Stiffness, Hypertension, Cardiovascular Diseases
09/24
09/24
HOPE-IPF, NCT02551068: High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

Recruiting
N/A
88
Canada
60% Oxygen, Standard of Care
University of British Columbia, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
12/26
12/26
NCT05582044: Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction

Recruiting
N/A
60
Canada
Lower-body Negative Pressure (-25 mmHg), Lower-body Negative Pressure (-15 mmHg), Lower-body Neutral Pressure (0 mmHg)
University of British Columbia
Heart Failure With Preserved Ejection Fraction
08/24
08/24
COPD, NCT05962164: Passive Heat Therapy for People With

Recruiting
N/A
32
Canada
Passive Heat Therapy, Lower-leg Hot Water Immersion, Footbath, Sham Immersion
University of British Columbia, Canadian Lung Association
COPD, Cardiovascular Diseases
12/24
12/24
 

Download Options